The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to all

PDF) Pre-clinical modelling of ROS1+ non-small cell lung cancer

Inna Khodos's research works Memorial Sloan Kettering Cancer

A clinically compatible drug‐screening platform based on

Small cell transformation of ROS1 fusion-positive lung cancer

Monika DAVARE, Professor (Associate), PhD

CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines

Gregory J. Riely's research works

The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to

A focal adhesion kinase-YAP signaling axis drives drug tolerant

Establishment and characterization of a cell line and patient

Monika DAVARE, Professor (Associate), PhD

The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to

Gregory J. Riely's research works

A focal adhesion kinase-YAP signaling axis drives drug tolerant